The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor ...

In this video from Clinical Trials at the Summit, Lejla Vajzovic, MD, FASRS, of Duke Eye Center, discusses tyrosine kinase inhibitors and gene therapy as different approaches for wet age-related ...

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer ...

In relapsing-remitting multiple sclerosis, activation of the peripheral immune system can lead to focal inflammation within the CNS. Over the past three decades, therapeutic development has been ...

NHS England » NHS England appoints two new cancer drugs expert to help patients benefit from a “treatment revolution” ...

LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) ha ...

Panelist discusses how Bruton tyrosine kinase inhibitors fit into real-world practice with community physicians often using ...

Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.